Toward molecular neuroeconomics of obesity

Because obesity is a risk factor for many serious illnesses such as diabetes, better understandings of obesity and eating disorders have been attracting attention in neurobiology, psychiatry, and neuroeconomics. This paper presents future study directions by unifying (i) economic theory of addiction and obesity (Becker and Murphy, 1988; Levy 2002; Dragone 2009), and (ii) recent empirical findings in neuroeconomics and neurobiology of obesity and addiction. It is suggested that neurobiological substrates such as adiponectin, dopamine (D2 receptors), endocannabinoids, ghrelin, leptin, nesfatin-1, norepinephrine, orexin, oxytocin, serotonin, vasopressin, CCK, GLP-1, MCH, PYY, and stress hormones (e.g., CRF) in the brain (e.g., OFC, VTA, NAcc, and the hypothalamus) may determine parameters in the economic theory of obesity. Also, the importance of introducing time-inconsistent and gain/loss-asymmetrical temporal discounting (intertemporal choice) models based on Tsallis’ statistics and incorporating time-perception parameters into the neuroeconomic theory is emphasized. Future directions in the application of the theory to studies in neuroeconomics and neuropsychiatry of obesity at the molecular level, which may help medical/psychopharmacological treatments of obesity (e.g., with sibutramine), are discussed.

💡 Research Summary

**
The paper proposes a “molecular neuroeconomics” framework that integrates classic economic models of addiction and obesity with contemporary neurobiological findings. Starting from Becker‑Murphy’s rational addiction theory and Levy’s rational obesity model, the author identifies the key parameters of the utility‑maximization problem—temporal discount rate (ρ), utility curvature (β), weight‑decay rate (δ), and mortality cost of excess weight (μ)—and maps each to specific neurochemical systems. Dopamine D2 receptor density, leptin, ghrelin, adiponectin, endocannabinoids, orexin, melanin‑concentrating hormone (MCH), oxytocin, serotonin, norepinephrine, and stress hormones (CRF) are argued to modulate these parameters through their actions in the ventral tegmental area (VTA), nucleus accumbens (NAcc), orbitofrontal cortex (OFC), medial frontal cortex (MFC) and hypothalamus.

Recognizing that human intertemporal choice is often time‑inconsistent and that gains and losses are discounted asymmetrically (the “sign effect”), the author adopts Tsallis‑statistics‑based q‑exponential discount functions for gains (q⁺) and losses (q⁻). When q < 1 the function approximates hyperbolic discounting, capturing impulsivity; when q → 1 it reduces to exponential discounting, reflecting consistency. By inserting these q‑exponential terms into the original objective functional, a new optimization problem J_q is derived, which predicts a higher steady‑state body weight (W_ss) than the classic model, aligning better with observed obesity prevalence.

The paper further discusses therapeutic implications. Sibutramine, a serotonin‑norepinephrine reuptake inhibitor, is hypothesized to lower ρ as well as q⁺ and q⁻, thereby reducing impulsive eating and time‑inconsistent preferences. Hormonal manipulations—leptin augmentation, ghrelin antagonism, adiponectin activation, orexin blockade—are presented as potential ways to adjust β, δ, and μ, offering a mechanistic route to personalized pharmacotherapy.

Finally, the author points out a paradox: medical advances that reduce the mortality cost of obesity (lower μ) could unintentionally raise the optimal body weight, emphasizing the need to consider both physiological and economic feedback loops in public‑health policy. In sum, the article establishes a comprehensive bridge from molecular signals through neural circuits to economic decision‑making, providing a quantitative scaffold for future experimental tests, drug development, and policy design aimed at combating obesity.